Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening.

Soucie JM, De Staercke C, Monahan PE, Recht M, Chitlur MB, Gruppo R, Hooper WC, Kessler C, Kulkarni R, Manco-Johnson MJ, Powell J, Pyle M, Riske B, Sabio H, Trimble S; US Hemophilia Treatment Center Network.

Transfusion. 2013 Jun;53(6):1217-25. doi: 10.1111/j.1537-2995.2012.03907.x. Epub 2012 Sep 24.

2.

Update of the human parvovirus B19 biology.

Servant-Delmas A, Morinet F.

Transfus Clin Biol. 2016 Feb;23(1):5-12. doi: 10.1016/j.tracli.2015.11.006. Epub 2016 Jan 6. Review.

PMID:
26778837
3.

Parvovirus transmission by blood products - a cause for concern?

Norja P, Lassila R, Makris M.

Br J Haematol. 2012 Nov;159(4):385-93. doi: 10.1111/bjh.12060. Epub 2012 Oct 1. Review.

PMID:
23025427
4.

Presence and significance of parvovirus B19 in blood and blood products.

Siegl G, Cassinotti P.

Biologicals. 1998 Jun;26(2):89-94. Review. No abstract available.

PMID:
9811511
5.

Parvoviruses and blood products.

Laub R, Strengers P.

Pathol Biol (Paris). 2002 Jun;50(5):339-48. Review.

PMID:
12116853
6.

[Genetic diversity of human erythroviruses. Consequences on infectious safety of plasma derivatives].

Servant-Delmas A, Mercier M, Laperche S, Lefrère JJ.

Transfus Clin Biol. 2009 Nov-Dec;16(5-6):482-8. doi: 10.1016/j.tracli.2009.09.001. Epub 2009 Oct 31. Review. French.

PMID:
19880339
7.

Human parvovirus B19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions.

Slavov SN, Kashima S, Pinto AC, Covas DT.

FEMS Immunol Med Microbiol. 2011 Aug;62(3):247-62. doi: 10.1111/j.1574-695X.2011.00819.x. Epub 2011 Jun 15. Review.

8.

Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus.

van Elsacker-Neile AM, Kroon FP, van der Ende ME, Salimans MM, Spaan WJ, Kroes AC.

Clin Infect Dis. 1996 Dec;23(6):1255-60. Review.

PMID:
8953068
9.

NAT screening of blood and plasma donations: evolution of technology and regulatory policy.

Tabor E, Epstein JS.

Transfusion. 2002 Sep;42(9):1230-7. Review. No abstract available.

PMID:
12430684
10.

Relevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature.

Verdonschot J, Hazebroek M, Merken J, Debing Y, Dennert R, Brunner-La Rocca HP, Heymans S.

Eur J Heart Fail. 2016 Dec;18(12):1430-1441. doi: 10.1002/ejhf.665. Epub 2016 Oct 17. Review.

PMID:
27748022
11.

Human Parvoviruses.

Qiu J, Söderlund-Venermo M, Young NS.

Clin Microbiol Rev. 2017 Jan;30(1):43-113. Review.

PMID:
27806994
12.

Safety Issues of Plasma-Derived Products for Treatment of Inherited Bleeding Disorders.

Farrugia A.

Semin Thromb Hemost. 2016 Jul;42(5):583-8. doi: 10.1055/s-0036-1571314. Epub 2016 Apr 14. Review.

PMID:
27077709
13.

PARV4: an emerging tetraparvovirus.

Matthews PC, Malik A, Simmons R, Sharp C, Simmonds P, Klenerman P.

PLoS Pathog. 2014 May 1;10(5):e1004036. doi: 10.1371/journal.ppat.1004036. eCollection 2014 May. Review. No abstract available.

14.

Recent advances in the development and use of plasma concentrates.

Soutar RL.

Br J Hosp Med. 1994 Feb 2-15;51(3):119-22. Review.

PMID:
8193836

Supplemental Content

Support Center